Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Executive Summary

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

You may also be interested in...



Califf: More Learning Necessary During Generic Drug Lifecycle

The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.

Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D

Revealing that the pegylated IL-10 therapy acquired in the Armo buyout two years ago has failed a pair of Phase II NSCLC trials, Lilly said it plans no further studies with the drug. Trulicity and Taltz led Lilly’s continuing growth story.

Cancer Drugs: US FDA Looks Outside For Help On Generic Labeling Updates

Under the Oncology Center of Excellence’s Project Renewal, agency has contracted with consulting firm Deloitte to establish subject matter expert research teams that will review published literature on off-patent drugs and suggest labeling updates.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel